Literature DB >> 11000231

Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1.

B Schramm1, M L Penn, E H Palacios, R M Grant, F Kirchhoff, M A Goldsmith.   

Abstract

Epidemiological studies have shown that human immunodeficiency virus type 2 (HIV-2) is markedly less pathogenic than HIV-1 in vivo. Individuals infected with HIV-2 exhibit a remarkably slow rate of disease development, and these clinical properties have been attributed presumptively to an "attenuated" phenotype of HIV-2 itself. Here, we investigated the impact of coreceptor usage on the cytopathicity of HIV-2 and compared its pathogenic potential with that of HIV-1 in a unique human lymphoid histoculture model. We found that HIV-2 strains, as well as closely related simian immunodeficiency viruses (SIV), displayed mildly or highly aggressive cytopathic phenotypes depending on their abilities to use the coreceptor CCR5 or CXCR4, respectively. A side-by-side comparison of primary X4 HIV-1 and HIV-2 strains revealed similar, high degrees of cytopathicity induced by both HIV types. Furthermore, we found that HIV-2 coreceptor specificity for CCR5 and CXCR4 determined the target cell population for T-cell depletion in lymphoid tissue. Finally, utilization of the alternate coreceptors BOB and Bonzo did not significantly increase the cytopathic properties of HIV-2. These findings demonstrate that coreceptor preference is a key regulator of target cell specificity and the cytopathic potential of HIV-2, with indistinguishable rules compared with HIV-1. Moreover, HIV-2 strains are not characterized by an intrinsically lower cytopathicity than HIV-1 strains. Therefore, direct cytopathic potential per se does not explain the unique behavior of HIV-2 in people, highlighting that other unknown factors need to be elucidated as the basis for their lesser virulence in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000231      PMCID: PMC112391          DOI: 10.1128/jvi.74.20.9594-9600.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Expression cloning of new receptors used by simian and human immunodeficiency viruses.

Authors:  H K Deng; D Unutmaz; V N KewalRamani; D R Littman
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

2.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.

Authors:  C C Bleul; L Wu; J A Hoxie; T A Springer; C R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

3.  Experimental HIV infection of human lymphoid tissue: correlation of CD4+ T cell depletion and virus syncytium-inducing/non-syncytium-inducing phenotype in histocultures inoculated with laboratory strains and patient isolates of HIV type 1.

Authors:  S Glushakova; B Baibakov; J Zimmerberg; L B Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  1997-04-10       Impact factor: 2.205

4.  Infection of human tonsil histocultures: a model for HIV pathogenesis.

Authors:  S Glushakova; B Baibakov; L B Margolis; J Zimmerberg
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

5.  Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop.

Authors:  Z Chen; P Telfier; A Gettie; P Reed; L Zhang; D D Ho; P A Marx
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.

Authors:  F Gao; L Yue; D L Robertson; S C Hill; H Hui; R J Biggar; A E Neequaye; T M Whelan; D D Ho; G M Shaw
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  HIV-2-infected patients survive longer than HIV-1-infected patients.

Authors:  H Whittle; J Morris; J Todd; T Corrah; S Sabally; J Bangali; P T Ngom; M Rolfe; A Wilkins
Journal:  AIDS       Date:  1994-11       Impact factor: 4.177

8.  9-year HIV-2-associated mortality in an urban community in Bissau, west Africa.

Authors:  A G Poulsen; P Aaby; O Larsen; H Jensen; A Nauclér; I M Lisse; C B Christiansen; F Dias; M Melbye
Journal:  Lancet       Date:  1997-03-29       Impact factor: 79.321

9.  Reduced rate of disease development after HIV-2 infection as compared to HIV-1.

Authors:  R Marlink; P Kanki; I Thior; K Travers; G Eisen; T Siby; I Traore; C C Hsieh; M C Dia; E H Gueye
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  19 in total

1.  Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection.

Authors:  Rui Soares; Russell Foxall; Adriana Albuquerque; Catarina Cortesão; Miguel Garcia; Rui M M Victorino; Ana E Sousa
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

2.  Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status.

Authors:  J F Kreisberg; D Kwa; B Schramm; V Trautner; R Connor; H Schuitemaker; J I Mullins; A B van't Wout; M A Goldsmith
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal.

Authors:  N N Zheng; N B Kiviat; P S Sow; S E Hawes; A Wilson; H Diallo-Agne; C W Critchlow; G S Gottlieb; L Musey; M J McElrath
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

Authors:  Adam MacNeil; Abdoulaye Dieng Sarr; Jean-Louis Sankalé; Seema Thakore Meloni; Souleymane Mboup; Phyllis Kanki
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  Cytopathic effects of non-syncytium-inducing and syncytium-inducing human immunodeficiency virus type 1 variants on different CD4(+)-T-cell subsets are determined only by coreceptor expression.

Authors:  D Kwa; J Vingerhoed; B Boeser-Nunnink; S Broersen; H Schuitemaker
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  HIV-2 infection is associated with preserved GALT homeostasis and epithelial integrity despite ongoing mucosal viral replication.

Authors:  S M Fernandes; A R Pires; P Matoso; C Ferreira; H Nunes-Cabaço; L Correia; E Valadas; J Poças; P Pacheco; H Veiga-Fernandes; R B Foxall; A E Sousa
Journal:  Mucosal Immunol       Date:  2017-05-17       Impact factor: 7.313

7.  Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection.

Authors:  Wim Jennes; Makhtar Camara; Tandakha Dièye; Souleymane Mboup; Luc Kestens
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Biological signature characteristics of primary isolates from human immunodeficiency virus type 1 group O in ex vivo human tonsil histocultures.

Authors:  Silvia Geuenich; Lars Kaderali; Ina Allespach; Serkan Sertel; Oliver T Keppler
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

9.  Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.

Authors:  Andreas Jekle; Birgit Schramm; Prerana Jayakumar; Verena Trautner; Dominique Schols; Erik De Clercq; John Mills; Suzanne M Crowe; Mark A Goldsmith
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.

Authors:  Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.